Return to Today's science sparks archives

2010-01-04

Fig 1. Final closure of lower uterine segment with #0 Gortex cerclage preserving the right uterine vasculature.

Fig 1. Final closure of lower uterine segment with #0 Gortex cerclage preserving the right uterine vasculature.
  • Abu-Rustum NR, Tal MN, DeLair D, Shih K, Sonoda Y

  • Gynecol Oncol. 2010 Jan;116(1):151-2.

2010-01-05

Fig 3. The binding sites for individual residues of peptide substrate (HSSKLQ) and the key protease residues interacting with the sidechains of the substrate residue through hydrogen bonding or hydrophobic interactions.

Fig 3. The binding sites for individual residues of peptide substrate (HSSKLQ) and the key protease residues interacting with the sidechains of the substrate residue through hydrogen bonding or hydrophobic interactions.
  • Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT

  • Proteins. 2009 Dec;77(4):984-93.

2010-01-06

Fig 2. Diagram of pelvic lymphatic drainage.

Fig 2. Diagram of pelvic lymphatic drainage.
  • Cibula D, Abu-Rustum NR

  • Gynecol Oncol. 2010 Jan;116(1):33-7.

2010-01-07

Fig 2. X-ray structure rendering of PD166326.

Fig 2. X-ray structure rendering of PD166326.
  • Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H

  • Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.

2010-01-08

Fig 2. Change in the primary endpoint, Ki-67, by tumor grade.

Fig 2. Change in the primary endpoint, Ki-67, by tumor grade.
  • Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ

  • Breast Cancer Res Treat. 2010 Jan;119(1):137-44.

2010-01-11

Fig 2. Clinical appearance of the lesion (case 1) with mapped margins after dermoscopic examination.

Fig 2. Clinical appearance of the lesion (case 1) with mapped margins after dermoscopic examination.
  • Terushkin V, Wang SQ

  • Dermatol Surg. 2009 Dec;35(12):2031-5.

2010-01-13

Fig 3. The choice of optimal strategy for administering adjuvant chemotherapy to radical cystectomy is illustrated in all patients.

Fig 3. The choice of optimal strategy for administering adjuvant chemotherapy to radical cystectomy is illustrated in all patients.
  • Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH; International Bladder Cancer Nomogram Consortium

  • Cancer. 2009 Dec 1;115(23):5460-9

2010-01-14

 Fig 5.(a) Asymmetrically pigmented adnexal openings (arrowhead) and brown streaks between adnexal openings (arrows) are observed with dermoscopy (case 8).

Fig 5.(a) Asymmetrically pigmented adnexal openings (arrowhead) and brown streaks between adnexal openings (arrows) are observed with dermoscopy (case 8).
  • Ahlgrimm-Siess V, Massone C, Scope A, Fink-Puches R, Richtig E, Wolf IH, Koller S, Gerger A, Smolle J, Hofmann-Wellenhof R

  • Br J Dermatol. 2009 Dec;161(6):1307-16.

2010-01-15

Fig 1. Distinct Spatial Patterns of siRNAs and piRNAs Mapped to mRNAs.

Fig 1. Distinct Spatial Patterns of siRNAs and piRNAs Mapped to mRNAs.
  • Robine N, Lau NC, Balla S, Jin Z, Okamura K, Kuramochi-Miyagawa S, Blower MD, Lai EC

  • Curr Biol. 2009 Dec 29;19(24):2066-76.

2010-01-18

Fig 1. Potential opposing effects of MC1R variant status upon risk of BRAF-mutant melanoma.

Fig 1. Potential opposing effects of MC1R variant status upon risk of BRAF-mutant melanoma.
  • Thomas NE, Kanetsky PA, Begg CB, Conway K, Berwick M

  • J Invest Dermatol. 2010 Jan;130(1):12-4.

2010-01-19

Fig 4. Armadillo, E-cadherin, and {alpha}-catenin protein levels are increased significantly in lgl mutants, suggesting that the loss of lgl stabilizes adherens junctions.

Fig 4. Armadillo, E-cadherin, and {alpha}-catenin protein levels are increased significantly in lgl mutants, suggesting that the loss of lgl stabilizes adherens junctions.
  • Kaplan NA, Liu X, Tolwinski NS

  • Genetics. 2009 Nov;183(3):897-904.

2010-01-20

Fig 1. Anatomy after pancreaticoduodenectomy with partial gastrectomy before single limb reconstruction.

Fig 1. Anatomy after pancreaticoduodenectomy with partial gastrectomy before single limb reconstruction.
  • Grobmyer SR, Kooby D, Blumgart LH, Hochwald, SN

  • J Am Coll Surg. 2010 Jan;210(1):54-59.

2010-01-21

Figure 1. Survival of patients aged 65 years with astrocytoma (AST) or oligodendroglioma (OLI) according to (A) histology and grade.

Figure 1. Survival of patients aged 65 years with astrocytoma (AST) or oligodendroglioma (OLI) according to (A) histology and grade.
  • Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB, Abrey LE

  • Cancer. 2009 Dec 1;115(23):5534-40.

2010-01-22

Fig 1. Seeding of Established Tumors by CTCs.

Fig 1. Seeding of Established Tumors by CTCs.
  • Kim, MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH., Norton L, Massagué J

  • Cell, 2009 Dec 24; 139(7):1315-1326.

2010-01-25

Fig 4. Representative blots of tight junction proteins in vocal fold epithelia following sham and hypertonic challenge.

Fig 4. Representative blots of tight junction proteins in vocal fold epithelia following sham and hypertonic challenge.
  • Sivasankar M, Erickson E, Rosenblatt M, Branski RC

  • Otolaryngology 2010 Jan;142(1):79-84.

2010-01-26

Fig 1. The predicted probability of clear-cell histology according to BMI, showing an estimate based on a univariate logistic regression model.

Fig 1. The predicted probability of clear-cell histology according to BMI, showing an estimate based on a univariate logistic regression model.
  • Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P

  • BJU Int. 2009 Jul 6;105(1):16-20.

2010-01-27

Fig 1. Nasopharynx applicator set (Mick Radionuclear Instruments, Mount Vernon, NY).

Fig 1. Nasopharynx applicator set (Mick Radionuclear Instruments, Mount Vernon, NY).
  • Koutcher L, Lee N, Zelefsky M, Chan K, Cohen G, Pfister D, Kraus D, Wolden S

  • Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):130-7.

2010-01-28

Fig 1. Axial section of prostate and periprostatic fascias at midprostate: (a) anatomic (reproduced with permission from the Mayo Clinic).

Fig 1. Axial section of prostate and periprostatic fascias at midprostate: (a) anatomic (reproduced with permission from the Mayo Clinic).
  • Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B, Menon M, Montorsi F, Myers RP, Rocco B, Villers A

  • Eur Urol. 2009 Nov 11.

2010-01-29

Fig 3. BRCA1 IHC and methylation status.

Fig 3. BRCA1 IHC and methylation status.
  • Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S

  • Cancer Res. 2009 Nov 1;69(21):8231-5.

2010-02-01

Fig 1. Survival curves of TET2 mutated and unmutated patients with non-indolent systemic mastocytosis (n=29).

Fig 1. Survival curves of TET2 mutated and unmutated patients with non-indolent systemic mastocytosis (n=29).
Highly cited
  • Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG

  • Leukemia. 2009 May;23(5):900-4.

2010-02-02

Fig 4.  WSTF is critical for the maintenance of gamma-H2A.X phosphorylation after DNA damage.

Fig 4. WSTF is critical for the maintenance of gamma-H2A.X phosphorylation after DNA damage.
Highly cited
  • Xiao A, Li H, Shechter D, Ahn SH, Fabrizio LA, Erdjument-Bromage H, Ishibe-Murakami S, Wang B, Tempst P, Hofmann K, Patel DJ, Elledge SJ, Allis CD

  • Nature. 2009 Jan 1;457(7225):57-62.

2010-02-03

Fig 2b. SP Cells Possess Stem Cell Properties and Are Enriched in Neurospheres.

Fig 2b. SP Cells Possess Stem Cell Properties and Are Enriched in Neurospheres.
Highly cited
  • Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC

  • Cell Stem Cell. 2009 Mar 6;4(3):226-35.

2010-02-04

Fig 1. Differentiation of Thymic and Induced Treg Cells.

Fig 1. Differentiation of Thymic and Induced Treg Cells.
Highly cited
  • Josefowicz SZ, Rudensky A

  • Immunity. 2009 May;30(5):616-25.

2010-02-05

Fig 2. JAK2V617F is acquired in cis with JAK2 SNP rs10974944.

Fig 2. JAK2V617F is acquired in cis with JAK2 SNP rs10974944.
Highly cited
  • Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL

  • Nat Genet. 2009 Apr;41(4):455-9.

2010-02-08

Fig 4. p53 Is Essential for Maintaining Hematopoietic Stem Cell Quiescence in Mef Null Mice.

Fig 4. p53 Is Essential for Maintaining Hematopoietic Stem Cell Quiescence in Mef Null Mice.
Highly cited
  • Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD

  • Cell Stem Cell. 2009 Jan 9;4(1):37-48.

2010-02-09

Fig 9. Stacking between different layers in the human telomeric G-quadruplex Form 3 in K+ solution.

Fig 9. Stacking between different layers in the human telomeric G-quadruplex Form 3 in K+ solution.
Highly cited
  • Lim KW, Amrane S, Bouaziz S, Xu W, Mu Y, Patel DJ, Luu KN, Phan AT

  • J Am Chem Soc. 2009 Apr 1;131(12):4301-9.

2010-02-10

Fig 3. IPS cells can be differentiated to neural tissue using dual-SMAD inhibition and are patternable to dopaminergic neurons and motoneurons.

Fig 3. IPS cells can be differentiated to neural tissue using dual-SMAD inhibition and are patternable to dopaminergic neurons and motoneurons.
Highly cited
  • Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L

  • Nat Biotechnol. 2009 Mar;27(3):275-80.

2010-02-11

Fig 1. Immunoglobulin-free light chain assay.

Fig 1. Immunoglobulin-free light chain assay.
Highly cited
  • Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group

  • Leukemia. 2009 Feb;23(2):215-24.

2010-02-12

Fig 3b. RD162 and MDV3100 impair AR nuclear translocation, DNA binding, and coactivator peptide recruitment.

Fig 3b. RD162 and MDV3100 impair AR nuclear translocation, DNA binding, and coactivator peptide recruitment.
Highly cited
  • Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL

  • Science. 2009 May 8;324(5928):787-90.

2010-02-15

Fig 2. Recurrence-free survival.

Fig 2. Recurrence-free survival.
Highly cited
  • Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team

  • Lancet. 2009 Mar 28;373(9669):1097-104.

2010-02-16

Fig 5a. NOTCH-HES1 signaling regulates KLF4 expression in the gut.

Fig 5a. NOTCH-HES1 signaling regulates KLF4 expression in the gut.
Highly cited
  • Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Meijerink J, Aifantis I, Basso G, Cordon-Cardo C, Ai W, Ferrando A

  • Nat Med. 2009 Jan;15(1):50-8.

2010-02-17

MicroRNAs and Cancer

MicroRNAs and Cancer
Highly cited
  • Ventura A, Jacks T

  • Cell. 2009 Feb 20;136(4):586-91.

2010-02-18

Fig 2a. Developmental regulation of proBDNF and p75 expression.

Fig 2a. Developmental regulation of proBDNF and p75 expression.
Highly cited
  • Yang J, Siao CJ, Nagappan G, Marinic T, Jing D, McGrath K, Chen ZY, Mark W, Tessarollo L, Lee FS, Lu B, Hempstead BL

  • Nat Neurosci. 2009 Feb;12(2):113-5.

2010-02-19

Fig 1a. Kaplan-Meier estimates according to surgery type- cardiovascular events.

Fig 1a. Kaplan-Meier estimates according to surgery type- cardiovascular events.
Highly cited
  • Huang WC, Elkin EB, Levey AS, Jang TL, Russo P

  • J Urol. 2009 Jan;181(1):55-61; discussion 61-2.

2010-02-22

Fig 4b. Immunofluorescent staining of germinal centre B cells (GL7+, green), follicular B cells (IgD+, red), and CD4+ T cells (blue) in spleens of Irf4fl/fl Foxp3Cre mice.

Fig 4b. Immunofluorescent staining of germinal centre B cells (GL7+, green), follicular B cells (IgD+, red), and CD4+ T cells (blue) in spleens of Irf4fl/fl Foxp3Cre mice.
Highly cited
  • Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY

  • Nature. 2009 Mar 19;458(7236):351-6.

2010-02-23

Fig 1a.  Cancer cells in primary tumours are surrounded by a complex microenvironment.

Fig 1a. Cancer cells in primary tumours are surrounded by a complex microenvironment.
Highly cited
  • Joyce JA, Pollard JW

  • Nat Rev Cancer. 2009 Apr;9(4):239-52.

2010-02-24

Fig 1. Survival curves for 89 patients with polycythemia vera stratified by their TET2 mutational status (14 mutated and 75 unmutated patients).

Fig 1. Survival curves for 89 patients with polycythemia vera stratified by their TET2 mutational status (14 mutated and 75 unmutated patients).
Highly cited
  • Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL

  • Leukemia. 2009 May;23(5):905-11.

2010-02-25

Awareness is needed of the potential for PML among rituximab-treated persons.

Awareness is needed of the potential for PML among rituximab-treated persons.
Highly cited
  • Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL

  • Blood. 2009 May 14;113(20):4834-40.

2010-02-26

The expert panel concluded that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic noncancer pain.

The expert panel concluded that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic noncancer pain.
Highly cited
  • Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel

  • J Pain. 2009 Feb;10(2):113-30.

2010-03-01

Fig 4. Lymph node assessment: large arrow illustrates a pathological node with the short axis shown as a solid line which should be measured and followed. Small arrow illustrates a non-pathological node which has a short axis <10 mm.

Fig 4. Lymph node assessment: large arrow illustrates a pathological node with the short axis shown as a solid line which should be measured and followed. Small arrow illustrates a non-pathological node which has a short axis <10 mm.
Highly cited
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J

  • Eur J Cancer. 2009 Jan;45(2):228-47.

2010-03-02

 Fig 3. The top panel shows red lesions on WLC and the bottom panels show normal green mucosa on NBIC. The biopsy after BCG therapy showed no tumour (granulomatous reaction).

Fig 3. The top panel shows red lesions on WLC and the bottom panels show normal green mucosa on NBIC. The biopsy after BCG therapy showed no tumour (granulomatous reaction).
  • Herr HW

  • BJU Int. 2010 Feb;105(3):314-6.

2010-03-03

Fig 1. Description of the three categories in which a patient can be classified (true negative [TN]; false negative [FN]; true positive [TP]). N–, node negative; N+, node positive; p, pathologic.

Fig 1. Description of the three categories in which a patient can be classified (true negative [TN]; false negative [FN]; true positive [TP]). N–, node negative; N+, node positive; p, pathologic.
  • Gonen M, Schrag D, Weiser MR

  • J Clin Oncol. 2009 Dec 20;27(36):6166-71.

2010-03-04

Fig 1. Microarray platform for detection of MUC1 O-glycopeptide-specific antibodies. Immunization of cancer patients with GalNAc-MUC1 break tolerance eliciting glycopeptide-specific antibodies.

Fig 1. Microarray platform for detection of MUC1 O-glycopeptide-specific antibodies. Immunization of cancer patients with GalNAc-MUC1 break tolerance eliciting glycopeptide-specific antibodies.
  • Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H

  • Cancer Res. 2010 Feb 15;70(4):1306-13.

2010-03-05

Fig 8. Role of cDCs in hepatic I/R.

Fig 8. Role of cDCs in hepatic I/R.
  • Bamboat ZM, Ocuin LM, Balachandran VP, Obaid H, Plitas G, DeMatteo RP

  • J Clin Invest. 2010 Feb 1;120(2):559-69.

2010-03-08

Fig 3.  Direct in vivo imaging of Abl expression in rat xenograft human CML model.

Fig 3. Direct in vivo imaging of Abl expression in rat xenograft human CML model.
  • Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, Larson SM

  • J Nucl Med. 2010 Jan;51(1):121-9.

2010-03-09

Fig 4. The Predicted Binding Mode of GD2 in the Antigen Binding Surface of a Fab Fragment of 3F8 Antibody.

Fig 4. The Predicted Binding Mode of GD2 in the Antigen Binding Surface of a Fab Fragment of 3F8 Antibody.
  • Tong W, Gagnon M, Sprules T, Gilbert M, Chowdhury S, Meerovitch K, Hansford K, Purisima EO, Blankenship JW, Cheung NK, Gehring K, Lubell WD, Saragovi HU

  • Chem Biol. 2010 Feb 26;17(2):183-194.

2010-03-10

Fig 1. PriA replisome loading. PriA can load a replisome to various DNA structures.

Fig 1. PriA replisome loading. PriA can load a replisome to various DNA structures.
  • Gabbai CB, Marians KJ

  • DNA Repair (Amst). 2010 Mar 2;9(3):202-209.

2010-03-11

Fig 2. Multiple mechanisms leading to aneuploidy.

Fig 2. Multiple mechanisms leading to aneuploidy.
  • Schvartzman JM, Sotillo R, Benezra R

  • Nat Rev Cancer. 2010 Feb;10(2):102-15.

2010-03-12

Fig 1. Seventh edition TNM classifications.

Fig 1. Seventh edition TNM classifications.
  • Rice TW, Blackstone EH, Rusch VW

  • J Thorac Cardiovasc Surg. 2010 Mar;139(3):527-9.

2010-03-15

Fig 1. Representative examples of immunohistochemical staining by p-AKT, PTEN, p-TSC2, p-mTOR, p-eIF4E, p-S6, and p-Erk1/2 (from left column) of NSCLC specimens.

Fig 1. Representative examples of immunohistochemical staining by p-AKT, PTEN, p-TSC2, p-mTOR, p-eIF4E, p-S6, and p-Erk1/2 (from left column) of NSCLC specimens.
  • Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J, Travis WD

  • Clin Cancer Res. 2010 Jan 1;16(1):240-8.

2010-03-16

Fig. 2. Immunostaining for carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein; CEACAM1) in muscle-invasive bladder tumors.

Fig. 2. Immunostaining for carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein; CEACAM1) in muscle-invasive bladder tumors.
  • Tilki D, Singer BB, Shariat SF, Behrend A, Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O, Ergün S

  • Eur Urol. 2009 May 28.

2010-03-17

Fig 4. Expression of Merlin and Depletion of DCAF1 Induce a Largely Overlapping Gene Expression Program.

Fig 4. Expression of Merlin and Depletion of DCAF1 Induce a Largely Overlapping Gene Expression Program.
  • Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG

  • Cell. 2010 Feb 19;140(4):477-490.

2010-03-18

Fig 3. In-field local progression-free survival for all patients treated with intraoperative radiation therapy.

Fig 3. In-field local progression-free survival for all patients treated with intraoperative radiation therapy.
  • Perry DJ, Chan K, Wolden S, Zelefsky MJ, Chiu J, Cohen G, Zaider M, Kraus D, Shah J, Lee N

  • Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1140-6.

2010-03-19

Fig 1. Micro–computed tomography (micro-CT) detects the growth of primary lung cancers in mice.

Fig 1. Micro–computed tomography (micro-CT) detects the growth of primary lung cancers in mice.
  • Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, Jacks T

  • Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):973-7.

2010-03-22

Fig 5. Magnetic resonance image of benign giant-cell tumor.

Fig 5. Magnetic resonance image of benign giant-cell tumor.
  • Domovitov SV, Healey JH

  • Ann Surg Oncol. 2010 Mar;17(3):694-701.

2010-03-23

Fig 1. Polarized cancer cell invasion along dorsal root ganglion (DRG) neurons.

Fig 1. Polarized cancer cell invasion along dorsal root ganglion (DRG) neurons.
  • Gil Z, Cavel O, Kelly K, Brader P, Rein A, Gao SP, Carlson DL, Shah JP, Fong Y, Wong RJ

  • J Natl Cancer Inst. 2010 Jan 20;102(2):107-18.

2010-03-24

Fig. 3. Nomogram for biochemical freedom from failure (BFFF). EBRT = external beam radiotherapy; D90 = minimum dose to 90% of the prostate volume.

Fig. 3. Nomogram for biochemical freedom from failure (BFFF). EBRT = external beam radiotherapy; D90 = minimum dose to 90% of the prostate volume.
  • Potters L, Roach M 3rd, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW

  • Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1061-5.

2010-03-25

Thiotepa/topotecan/carboplatin may help consolidate remission of poor prognosis pediatric central nervous system tumors.

Thiotepa/topotecan/carboplatin may help consolidate remission of poor prognosis pediatric central nervous system tumors.
  • Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ

  • Pediatr Blood Cancer. 2010 Apr;54(4):591-5.

2010-03-26

Supplementary Figure 1. Transheterozygous mir-9a [J22]/[E39] mutant wing pouch doubly stained for Wingless (Wg, green) and cleaved caspase-3 (c Casp3, red).

Supplementary Figure 1. Transheterozygous mir-9a [J22]/[E39] mutant wing pouch doubly stained for Wingless (Wg, green) and cleaved caspase-3 (c Casp3, red).
  • Bejarano F, Smibert P, Lai EC

  • Dev Biol. 2009 Nov 26.

2010-03-29

Fig 1. The best percentage prostate-specific antigen (PSA) change from baseline is shown.

Fig 1. The best percentage prostate-specific antigen (PSA) change from baseline is shown.
  • Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M

  • Cancer. 2009 Dec 1;115(23):5541-9.

2010-03-30

Extent of Pelvic Lymph Node Dissection During Radical Cystectomy: Where and Why!

Extent of Pelvic Lymph Node Dissection During Radical Cystectomy: Where and Why!
  • Herr HW

  • Eur Urol. 2009 Oct 31.

2010-03-31

Fig 2. Combined Kelly clamp and Impact transection of liver parenchyma.

Fig 2. Combined Kelly clamp and Impact transection of liver parenchyma.
  • Patrlj L, Tuorto S, Fong Y

  • J Am Coll Surg. 2009 Sept;210(1):39-44.

2010-04-01

Fig 3. Constitutive expression of Def does not rescue Dif dl hemocyte phenotypes.

Fig 3. Constitutive expression of Def does not rescue Dif dl hemocyte phenotypes.
  • Matova N, Anderson KV

  • J Cell Sci. 2010 Feb 15;123(Pt 4):627-33.